Regulatory Scrutiny and Growth Concerns Weigh on Hims & Hers

Hims & Hers faces an SEC investigation into its weight-loss drug segment and issued a disappointing revenue forecast, triggering analyst downgrades and a steep stock decline.

Shares of telehealth provider Hims & Hers are facing significant headwinds following a disappointing forecast and the revelation of a new regulatory probe. Despite posting strong fourth-quarter results, these dual challenges have unsettled investors and prompted analyst downgrades.

SEC Inquiry Targets Key Growth Segment

A major source of pressure is a formal investigation by the U.S. Securities and Exchange Commission (SEC). In a required filing, the company disclosed that the regulator has requested information concerning public statements and disclosures related to its compounded semaglutide products. This development carries substantial weight, as the weight-loss segment has recently emerged as a central driver for the company's expansion. The SEC probe compounds existing uncertainties stemming from FDA oversight and ongoing patent disputes within this competitive market.

Concurrently, the company's guidance disappointed the market. Management's revenue forecast for the first quarter of 2026 sits between $600 million and $625 million, notably below analyst consensus estimates of approximately $654 million. This combination of a growth slowdown and regulatory pressure triggered immediate downgrades from firms including Citigroup and BTIG.

Strong Operational Performance Overshadowed

These concerns have eclipsed what was otherwise a robust operational performance for the fourth quarter of 2025. The company reported revenue growth of 28%, reaching nearly $618 million. Furthermore, earnings per share of $0.08 surpassed market expectations.

In a strategic move to secure growth beyond its challenged U.S. operations, Hims & Hers has announced the acquisition of the health platform Eucalyptus. The deal, valued at up to $1.15 billion, is designed to accelerate international expansion into key markets such as Germany, the United Kingdom, Australia, and Japan. This acquisition signals a clear attempt by management to reduce reliance on the heavily regulated domestic market through international diversification.

Share Price Under Severe Pressure

The market has reacted harshly to this climate of uncertainty. Since the beginning of the year, the stock has lost nearly 53% of its value. It currently trades around €13.50, hovering just above its 52-week low.

The path forward for Hims & Hers now heavily depends on how swiftly it can resolve the SEC's inquiries. Until the Eucalyptus acquisition is finalized, which is expected by mid-2026, the equity will remain caught between an aggressive global growth strategy and mounting legal risks in its core business.